Characterization of Circulating IL-10-Producing Cells in Septic Shock Patients: A Proof of Concept Study.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 07 10 2020
accepted: 21 12 2020
entrez: 22 2 2021
pubmed: 23 2 2021
medline: 29 6 2021
Statut: epublish

Résumé

Sepsis is a worldwide health priority characterized by the occurrence of severe immunosuppression associated with increased risk of death and secondary infections. Interleukin 10 (IL-10) is a potent immunosuppressive cytokine which plasma concentration is increased in septic patients in association with deleterious outcomes. Despite studies evaluating IL-10 production in specific subpopulations of purified cells, the concomitant description of IL-10 production in monocytes and lymphocytes in septic patients' whole blood has never been performed. In this pilot study, we characterized IL-10 producing leukocytes in septic shock patients through whole blood intracellular staining by flow cytometry. Twelve adult septic shock patients and 9 healthy volunteers were included. Intracellular tumor necrosis factor-α (TNFα) and IL-10 productions after lipopolysaccharide stimulation by monocytes and IL-10 production after PMA/Ionomycine stimulation by lymphocytes were evaluated. Standard immunomonitoring (HLA-DR expression on monocytes, CD4+ T lymphocyte count) of patients was also performed. TNFα expression by stimulated monocytes was reduced in patients compared with controls while IL-10 production was increased. This was correlated with a reduced monocyte HLA-DR expression. B cells, CD4+, and CD4- T lymphocytes were the three circulating IL-10 producing lymphocyte subsets in both patients and controls. No difference in IL-10 production between patients and controls was observed for B and CD4- T cells. However, IL-10 production by CD4+ T lymphocytes significantly increased in patients in parallel with reduced CD4+ T cells number. Parameters reflecting altered monocyte (increased IL-10 production, decreased HLA-DR expression and decreased TNFα synthesis) and CD4+ T lymphocyte (increased IL-10 production, decreased circulating number) responses were correlated. Using a novel technique for intracellular cytokine measurement in whole blood, our results identify monocytes and CD4+ T cells as the main IL-10 producers in septic patients' whole blood and illustrate the development of a global immunosuppressive profile in septic shock. Overall, these preliminary results add to our understanding of the global increase in IL-10 production induced by septic shock. Further research is mandatory to determine the pathophysiological mechanisms leading to such increased IL-10 production in monocytes and CD4+ T cells.

Identifiants

pubmed: 33613540
doi: 10.3389/fimmu.2020.615009
pmc: PMC7890231
doi:

Substances chimiques

Antigens, CD 0
HLA-DR Antigens 0
IL10 protein, human 0
Lipopolysaccharides 0
Tumor Necrosis Factor-alpha 0
Interleukin-10 130068-27-8
Brefeldin A 20350-15-6
Ionomycin 56092-81-0
Tetradecanoylphorbol Acetate NI40JAQ945

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

615009

Informations de copyright

Copyright © 2021 Fabri, Kandara, Coudereau, Gossez, Abraham, Monard, Cour, Rimmelé, Argaud, Monneret and Venet.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

PLoS One. 2017 Jun 19;12(6):e0179050
pubmed: 28628675
J Immunol Res. 2018 Aug 5;2018:3758713
pubmed: 30155493
Crit Care Med. 2003 Jul;31(7):2068-71
pubmed: 12847405
N Engl J Med. 2017 Aug 3;377(5):414-417
pubmed: 28658587
Crit Care Med. 2001 Jan;29(1):129-33
pubmed: 11176172
J Surg Res. 2008 Jun 1;147(1):1-8
pubmed: 17720196
Semin Immunol. 2019 Aug;44:101323
pubmed: 31685302
Am J Respir Crit Care Med. 2002 Dec 1;166(11):1475-82
pubmed: 12406851
Burns. 2008 Dec;34(8):1158-62
pubmed: 18538934
Annu Rev Immunol. 2001;19:683-765
pubmed: 11244051
Shock. 2017 Mar;47(3):318-322
pubmed: 27513085
Semin Immunol. 2019 Aug;44:101344
pubmed: 31727465
Immunol Rev. 2008 Jun;223:391-421
pubmed: 18613849
Immunology. 2008 May;124(1):13-22
pubmed: 18346152
J Immunol. 2000 Sep 1;165(5):2783-9
pubmed: 10946310
Lancet Infect Dis. 2013 Mar;13(3):260-8
pubmed: 23427891
Cytometry B Clin Cytom. 2013 Jan-Feb;84(1):59-62
pubmed: 22987669
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
Annu Rev Immunol. 2012;30:221-41
pubmed: 22224776
J Crit Care. 1997 Dec;12(4):183-7
pubmed: 9459114
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Trends Immunol. 2021 Jan;42(1):3-5
pubmed: 33214057
Crit Care Med. 2004 Nov;32(11):2329-31
pubmed: 15640650
Am J Transplant. 2007 May;7(5):1215-23
pubmed: 17331111
Med Sci Monit. 2016 Jul 07;22:2374-8
pubmed: 27389933
Biochem Biophys Res Commun. 2003 Sep 5;308(4):840-6
pubmed: 12927795
Pathobiology. 1999;67(5-6):253-6
pubmed: 10725796
Blood. 2000 Jul 1;96(1):218-23
pubmed: 10891454
Curr Opin Immunol. 2013 Aug;25(4):477-83
pubmed: 23725873
J Immunol. 2018 Apr 1;200(7):2418-2425
pubmed: 29459404
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Annu Rev Immunol. 2011;29:71-109
pubmed: 21166540
J Exp Med. 1991 Nov 1;174(5):1209-20
pubmed: 1940799
Am J Respir Crit Care Med. 2017 Aug 15;196(4):458-470
pubmed: 28107024
J Interferon Cytokine Res. 2012 Aug;32(8):341-9
pubmed: 22799563
Immunol Lett. 2019 Nov;215:48-59
pubmed: 31442542
J Leukoc Biol. 2010 Aug;88(2):303-11
pubmed: 20356901
Cytokine. 2018 Apr;104:78-84
pubmed: 28969945

Auteurs

Astrid Fabri (A)

Hospices Civils de Lyon, Edouard Herriot Hospital, Immunology Laboratory, Lyon, France.
Hospices Civils de Lyon-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon 1, Villeurbanne, France.

Khalil Kandara (K)

Hospices Civils de Lyon, Edouard Herriot Hospital, Immunology Laboratory, Lyon, France.
Hospices Civils de Lyon-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon 1, Villeurbanne, France.

Rémy Coudereau (R)

Hospices Civils de Lyon, Edouard Herriot Hospital, Immunology Laboratory, Lyon, France.
Hospices Civils de Lyon-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon 1, Villeurbanne, France.

Morgane Gossez (M)

Hospices Civils de Lyon, Edouard Herriot Hospital, Immunology Laboratory, Lyon, France.
Hospices Civils de Lyon-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon 1, Villeurbanne, France.

Paul Abraham (P)

Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Céline Monard (C)

Hospices Civils de Lyon-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon 1, Villeurbanne, France.
Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Martin Cour (M)

Medical Intensive Care Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Thomas Rimmelé (T)

Hospices Civils de Lyon-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon 1, Villeurbanne, France.
Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Laurent Argaud (L)

Medical Intensive Care Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Guillaume Monneret (G)

Hospices Civils de Lyon, Edouard Herriot Hospital, Immunology Laboratory, Lyon, France.
Hospices Civils de Lyon-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon 1, Villeurbanne, France.

Fabienne Venet (F)

Hospices Civils de Lyon, Edouard Herriot Hospital, Immunology Laboratory, Lyon, France.
Hospices Civils de Lyon-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon 1, Villeurbanne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH